Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers

Sponsor
Nanjing First Hospital, Nanjing Medical University
Study ID
NCT04180007
Phase
PHASE2
Status
Unknown

Conditions

  • Apatinib
  • Metastasis
  • Thyroid

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    500 mg Apatinib given orally once a day for 12 wk prior to RAI (131I) treatment.

Study Details

The purpose of this study is to determine Safety and Efficacy of Radioactive Iodine (RAI) Treatment of Metastatic and Advanced Differentiated Thyroid Cancers by Pretreatment With Apatinib for the Neoadjuvant Regimen

Key Dates

Start date
Apr 10, 2019
Status verified
Nov 2019
Primary completion
Apr 10, 2020
Completion
May 30, 2020

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Neoadjuvant arm
    Patients receive Apatinib orally qd up to 12 wk.

Primary Outcome Measure

Overall response rate [ Time Frame: 4 month ]

Central Contacts

Related Studies